Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering
PARSIPPANY, N.J., Nov. 16, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced the pricing of its public offering of 7,000,000 shares of its common stock at a price of $6.50 per share. All of the 7,000,000 shares are newly issued and are being offered by Pacira, with expected net proceeds to Pacira of approximately $42.3 million after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Pacira has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares to cover over-allotments, if any.
Barclays Capital Inc. and Jefferies & Company, Inc. are acting as joint book-running managers for the offering. Piper Jaffray & Co., Wedbush PacGrow Life Sciences and Brean Murray, Carret & Co. are acting as co-managers for the offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. A copy of the final prospectus for this offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by calling 1-888-603-5847 or by emailing Barclaysprospectus@broadridge.com. A copy of the final prospectus may also be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, telephone: (877) 547-6340, email: Prospectus_Department@Jefferies.com.
Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPARELTM (bupivacaine liposome injectable suspension), was approved for administration into the surgical site to produce postsurgical analgesia by the U.S. Food and Drug Administration in October 2011. EXPAREL and two other commercially available products utilize the Pacira proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3570
Pure Communications Inc.
Jennifer Beugelmans, 646-596-7473
SOURCE Pacira Pharmaceuticals, Inc.